There are currently 1248 clinical trials in Seattle, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center and University of Washington Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
NCT06093672
Recruiting
The goal of this clinical trial is to compare the efficacy and safety of givinostat to hydroxyurea in Jak2V617F-positive high risk polycythemia vera patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: VA Puget Sound Health Care System - NAVREF - PPDS, Seattle, Washington
Conditions: Polycythemia Vera
Register for Updates
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778
Recruiting
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Swedish Cancer Institute /ID# 269538, Seattle, Washington
Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Virginia Mason Medical Center, Seattle, Washington
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
NCT03128034
Recruiting
This phase I/II trial studies the side effects and best dose of 211\^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia. Radioactive substances, such as astatine-211, linked to monoclonal antibodies, such as BC8, can bind to cancer cells and give off radiation which may help kill cancer cells and have less of an effect on healthy cells before d... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/16/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Mixed Phenotype Acute Leukemia
Register for Updates
A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
NCT05578092
Recruiting
This is a Phase 1/2, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579
Recruiting
The purpose of this Phase 3 study is to demonstrate the efficacy of DNTH103 as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/16/2025
Locations: Clinical Study Site, Seattle, Washington
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
The PEERLESS II Study
NCT06055920
Recruiting
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: University of Washington, Seattle, Washington
Conditions: Pulmonary Embolism
Register for Updates
StrokeNet Thrombectomy Endovascular Platform
NCT06289985
Recruiting
STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Harborview Medical Center, Seattle, Washington
Conditions: Ischemic Stroke
Register for Updates
National Collaborative to Improve Care of Children With Complex Congenital Heart Disease
NCT02852031
Recruiting
The purpose of this initiative is to improve care and outcomes for infants with HLHS by expanding the NPC-QIC national registry to gather clinical care process, outcome, and developmental data on infants with HLHS between diagnosis and 12 months of age, by improving the use of standards into everyday practice across pediatric cardiology centers, and by engaging parents as partners in the process.
Gender:
ALL
Ages:
15 months and below
Trial Updated:
06/16/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Hypoplastic Left Heart Syndrome (HLHS)
Register for Updates
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733
Recruiting
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main questions it aims to answer are: Does niraparib improve progression-free survival (PFS) compared to TMZ? Does niraparib improve overall survival (OS) compared to TMZ? Participants will be randomly assigned to one of two treatment arms: niraparib or TMZ. * study drug (Niraparib) or * comp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
Register for Updates
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT04175431
Recruiting
This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Prostate Adenocarcinoma
Register for Updates
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955
Recruiting
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Swedish Medical Center, Seattle, Washington +2 locations
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Register for Updates